Transition from parenteral treprostinil to selexipag aiming at hemodynamic targets in pulmonary arterial hypertension
This study showed that 3 of 5 patients (60.0%) with high-risk PAH reached PVR ≤ 4 WU and/or mPAP ≤ 40 mmHg by receiving intensive parenteral treprostinil therapy with significant improvements in 6MWD and NT-proBNP levels, and successfully transitioned to oral selexipag. We proposed that transition strategies from parenteral treprostinil to selexipag aiming at hemodynamic targets.
Authors
- Wook‐Jin Chung (ORCID: https://orcid.org/0000-0002-9767-7098)
- Albert Youngwoo Jang (ORCID: https://orcid.org/0000-0002-8802-268X)
- Taeil Yang (ORCID: https://orcid.org/0009-0003-3744-7084)
- Kyung Jin Ahn (ORCID: https://orcid.org/0000-0002-6286-3157)
- Joohan Kim (ORCID: https://orcid.org/0009-0002-1700-9960)
- Jina Yeo (ORCID: https://orcid.org/0000-0002-7923-8729)
- Min-Su Kim (ORCID: https://orcid.org/0000-0002-9186-9558)
- Y.S. Won (ORCID: https://orcid.org/0000-0003-4414-5159)
- Jihye Yoon (ORCID: https://orcid.org/0009-0001-0673-6006)
Institutions
- Gachon University (KR)
- Gachon University Gil Medical Center (KR)
Publication Details
- Journal
- Clinical Hypertension
- Published
- 2025-01-01
- DOI
- https://doi.org/10.5646/ch.2025.31.e5
- Citations
- 2
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 3.04
Funders
- Korea Medical Device Development Fund
- Gachon University
- Ministry of Trade, Industry and Energy
- Ministry of Food and Drug Safety
- Gil Medical Center, Gachon University
- Ministry of Science and ICT, South Korea
- Korea National Institute of Health